Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victoria Wang

Showing results (121-130 of 130) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 130 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 27, 2021
Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i>-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i>-Mutated TumorsJames M Cleary, Victoria Wang, Rebecca S Heist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2026
Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2Niamh Coleman, Zihan Wei, A John Iafrate, et al.
JCO Precision Oncology|February 9, 2022
Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol IIan E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, et al.
JCO Precision Oncology|June 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1IShivaani Kummar, Zihe Song, Kim A Reiss, et al.
Nature Genetics|November 7, 2017
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancersCollin M Blakely, Thomas B K Watkins, Wei Wu, et al.
Cancer Cell|February 5, 2010
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1Roel G W Verhaak, Katherine A Hoadley, Elizabeth Purdom, et al.
Blood|April 25, 2021
Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALLElisabeth Paietta, Kathryn G Roberts, Victoria Wang, et al.
Cell|August 27, 2025
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancersEmily Grist, Peter Dutey-Magni, Marina A Parry, et al.
Research Square|February 17, 2023
Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trialMarina A Parry, Emily Grist, Larissa Mendes, et al.
Cancer Discovery|June 9, 2021
Enhancer Hijacking Drives Oncogenic <i>BCL11B</i> Expression in Lineage-Ambiguous Stem Cell LeukemiaLindsey E Montefiori, Sonja Bendig, Zhaohui Gu, et al.
Pageof 13

Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 27, 2021
Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i>-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i>-Mutated TumorsJames M Cleary, Victoria Wang, Rebecca S Heist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2026
Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2Niamh Coleman, Zihan Wei, A John Iafrate, et al.
JCO Precision Oncology|February 9, 2022
Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol IIan E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, et al.
JCO Precision Oncology|June 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1IShivaani Kummar, Zihe Song, Kim A Reiss, et al.
Nature Genetics|November 7, 2017
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancersCollin M Blakely, Thomas B K Watkins, Wei Wu, et al.
Cancer Cell|February 5, 2010
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1Roel G W Verhaak, Katherine A Hoadley, Elizabeth Purdom, et al.
Blood|April 25, 2021
Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALLElisabeth Paietta, Kathryn G Roberts, Victoria Wang, et al.
Cell|August 27, 2025
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancersEmily Grist, Peter Dutey-Magni, Marina A Parry, et al.
Research Square|February 17, 2023
Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trialMarina A Parry, Emily Grist, Larissa Mendes, et al.
Cancer Discovery|June 9, 2021
Enhancer Hijacking Drives Oncogenic <i>BCL11B</i> Expression in Lineage-Ambiguous Stem Cell LeukemiaLindsey E Montefiori, Sonja Bendig, Zhaohui Gu, et al.
Pageof 13